K2 Principal Fund L.P. purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,156 shares of the medical instruments supplier’s stock, valued at approximately $1,990,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Westwood Holdings Group Inc. increased its position in Becton, Dickinson and by 24.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after acquiring an additional 205,721 shares in the last quarter. Colony Group LLC increased its position in Becton, Dickinson and by 2.1% in the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after acquiring an additional 239 shares in the last quarter. State Street Corp increased its position in Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp increased its position in Becton, Dickinson and by 1.3% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after acquiring an additional 453 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its position in Becton, Dickinson and by 35.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after acquiring an additional 11,300 shares in the last quarter. 87.91% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “K2 Principal Fund L.P. Invests $1.99 Million in Becton, Dickinson and Company (BDX) Stock” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/24/k2-principal-fund-l-p-invests-1-99-million-in-becton-dickinson-and-company-bdx-stock.html.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $224.23 on Friday. Becton, Dickinson and Company has a 1 year low of $161.29 and a 1 year high of $227.50. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The company has a market cap of $51,119.57, a P/E ratio of 23.63, a PEG ratio of 1.76 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the previous year, the company earned $2.12 EPS. Becton, Dickinson and’s revenue was down 2.0% on a year-over-year basis. research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.75 per share. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.34%. Becton, Dickinson and’s payout ratio is currently 62.80%.

In related news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

Several equities research analysts have weighed in on the stock. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Royal Bank Of Canada restated a “sector perform” rating and issued a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley raised their price objective on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Wells Fargo & Company restated a “positive” rating and issued a $235.00 price objective (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and currently has an average rating of “Buy” and an average target price of $217.08.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.